Genexine KRX:095700KOSDAQ
제넥신 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days4
Articles tracked15since Sep 11
In Q2 2026, Genexine reported revenue of ₩972m, up 44.7% year on year, and an operating loss of ₩10.5bn. Genexine (제넥신) appeared in 3 Korean news articles and 4 DART filings over the past seven days. Coverage peaked on Oct 26 with 3 articles.
Filing signals Private placement Dilution risk 4 quarters of losses Screener
Genexine quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩972m | +44.7% | −₩10.5bn | −₩26.3bn |
| Q1 2026 | ₩415m | +29.8% | −₩9.0bn | −₩12.4bn |
| Q4 2025 derived | ₩537m | +75.6% | −₩12.8bn | −₩14.6bn |
| Q3 2025 | ₩3.0bn | +1355.9% | −₩7.4bn margin −243.6% | ₩21.1bn |
| Q2 2025 | ₩672m | +95.0% | −₩7.5bn | −₩14.7bn |
| Q1 2025 | ₩320m | -84.6% | −₩8.5bn | −₩18.9bn |
| Q4 2024 derived | ₩306m | -80.1% | −₩7.6bn | −₩25.5bn |
| Q3 2024 | ₩209m | -43.2% | −₩10.3bn | −₩14.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Genexine top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest Genexine news Korean headlines
-
제넥신, 30억원 제3자배정 유상증자
2 more on this story · 2 outlets
- 제넥신, 30억원 규모 제3자배정 유상증자…“운영자금 확보 차원“더바이오 · Oct 16 16:41
- 제넥신, 30억원 규모 유상증자 실시매일경제 · Oct 16 17:59